Egetis Therapeutics AB(DE:P0F)
€0.98+0.04 (+4.84%)
DE:P0F
Egetis Therapeutics AB stock forecast
€0.98
At close:+0.04 (+4.84%)
Egetis Therapeutics AB (P0F) Stock Forecast & Price Target
P0F Analyst Ratings
Hold
0Buy1Hold0Sell
Based on 1 analysts giving stock ratings to Egetis Therapeutics AB in the past 3 months
P0F Stock 12 Month Forecast
Average Price Target
€1.01▲(4.09% Upside)Based on 1 Wall Street analysts offering 12 month price targets for Egetis Therapeutics AB in the last 3 months. The average price target is EUR 1.01 with a high forecast of EUR 1.01 and a low forecast of EUR 1.01. The average price target represents a 4.09% change from the last price of EUR 0.98.
Past 12 Months12 Month ForecastJan2026Oct2026
High€1.01
Average€1.01
Low€1.01
Highest Price TargetHighest€1.01Average Price Target€1.01Lowest Price TargetLowest€1.01
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Kristen Kluska | Cantor Fitzgerald | €2.98→€1.01 | hold | 4.09%Upside | Downgraded | 11/05/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Kristen KluskaCantor Fitzgerald | HoldDowngraded€2.98→€1.01 | 11/05/26 | 4.09%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
P0F Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 1 | 1 | 1 | 2 |
In the current month, P0F has received 1 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. P0F average Analyst price target in the past 3 months is 1.01.
P0F Financial Forecast
High€-0.01
Consensus€-0.01
Low€-0.01
P0F Earnings Forecast
Next quarter’s earnings estimate for P0F is -EUR 0.01 with a range of -EUR 0.01 to -EUR 0.01. The previous quarter’s EPS was -EUR 0.02. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€82.9M
Consensus€30.7M
Low€2.94M
P0F Sales Forecast
Next quarter’s sales forecast for P0F is EUR 30.68M with a range of EUR 2.94M to EUR 82.86M. The previous quarter’s sales results were EUR 1.94M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
P0F Stock Forecast FAQ
What is DE:P0F’s average 12-month price target, according to analysts?
Based on analyst ratings, Egetis Therapeutics AB’s 12-month average price target is €1.01.
What is DE:P0F’s upside potential, based on the analysts’ average price target?
Egetis Therapeutics AB has 4.09% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Egetis Therapeutics AB a Buy, Sell or Hold?
Egetis Therapeutics AB has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
What is Egetis Therapeutics AB’s share price target?
The average share price target for Egetis Therapeutics AB is €1.01. This is based on 1 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €1.01, and the lowest forecast is €1.01. The average share price target represents a 4.09% increase from the current price of €0.975.
What do analysts say about Egetis Therapeutics AB?
Egetis Therapeutics AB’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Street analysts.
How can I buy shares of Egetis Therapeutics AB?
To buy shares of DE:P0F, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
